TX-MYTHICAL-GAMES
Pudgy Penguins, the brand development company behind the series of globally recognized Pudgy Penguins characters, and next-generation gaming technology studio Mythical Games today announced a partnership to create a unique web3-enabled mobile video game. The partnership unites the creators of the globally recognized Pudgy Penguins characters and the gaming studio behind two of the most successful blockchain games ever, NFL Rivals and Blankos Block Party.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530595937/en/
Details of the forthcoming game developed in conjunction with Mythical Games were announced at Consensus 2024. The upcoming mobile game will be an immersive video game drawing upon the lore and humor that have made Pudgy Penguins so beloved, coupled with AAA quality, playability, and accessibility synonymous with Mythical Games' title NFL Rivals. The new game is scheduled to launch on the Mythical platform in 2025, home to NFL Rivals, with over 5 million players, and the Mythos Chain (MYTH), with over one million active wallets.
“Web3 in gaming is evolving quickly, but one thing that hasn’t changed is the need for games to be powered by strong communities and great gameplay,” said John Linden, Mythical Games CEO. “Pudgy Penguins is the only web3 project to truly go mainstream through their incredible retail partnerships with Walmart and Target and their rapidly growing social media following. We are excited to combine their efforts with a game that will be played by millions. Building this with Mythical Games on the Mythical Platform and Mythos Chain, already used by millions of consumers, is going to be a major driver to further push web3 with mainstream consumers.”
Luca Netz, CEO of Pudgy Penguins said: “When we decided to create a mobile-first AAA blockchain-based Pudgy Penguins game, working with Mythical Games is something that excited me. Our growth strategy that has reached millions, combined with Mythical Games’ experience and success with gaming, sets up this endeavor for success. We can’t wait to show the Pudgy Penguins community what’s in store and solicit their feedback as development ramps up.”
In the build-up to its release, Pudgy Penguins holders will be treated to exclusive content, sneak peeks of in-game footage and given the opportunity to help shape key aspects of the game’s development. The game is designed to appeal to the Pudgy Penguins community as well as the broader gaming market to further grow the Pudgy Penguins’ brand and ethos.
Ahead of the game's launch in 2025, interested players can join Pudgy Penguins Discord, and follow Pudgy Penguins (@pudgypenguins) and Mythical Games (@playmythical) Twitter/X accounts to stay updated on the upcoming game.
About Pudgy Penguins
Pudgy Penguins is dedicated to making Web3 accessible to everyone by creating innovative products that enable seamless onboarding. Their focus on community empowerment and building brand awareness has made them a leader in the Web3 space while also disrupting the traditional web2, retail sphere. They're committed to impacting the everyday consumer and shaping the future of Web3.
Learn more: https://www.pudgypenguins.com/
About Mythical Games
Acknowledged by Fast Company’s World Changing Ideas 2021 and recently Forbes’ Best Startup Employers (2024), Mythical Games is a next-generation game company creating world-class games and empowering players to take ownership of their in-game assets through the use of blockchain technology. The team has helped develop major franchises, including Call of Duty, Call of Duty Mobile, World of Warcraft, Diablo, Overwatch, Magic: The Gathering, EA Madden, Harry Potter Hogwarts Mystery, Marvel Strike Force, Modern Warfare 3, and Skylanders.
The Mythical Marketplace, the first in-game blockchain Marketplace on iOS and Android, provides gamers with ownership and control over the purchase and sale of digital assets, while the Mythical Platform protects gamers that may be new to blockchain through a custodial wallet for their digital items.
Mythical Games is one of the 22 founding member companies of the Mythos Foundation (http://mythos.foundation) utilizing the Mythos Chain as its blockchain and Mythos’ MYTH token as the utility token for the Mythical Marketplace.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530595937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom